Spotlight – following Humira in hidradenitis suppurativa

Data on three new therapies for the painful autoimmune disease hidradenitis suppurativa emerged last month, and one of these agents, UCB’s Bimzelx, will be heading to regulators later this year.

Many other projects are in development, including a round dozen in mid-stage trials. Important readouts due in the coming months include a data on a project from Moonlake Immunotherapeutics, for which expectations are particularly high. Here are the readouts to look out for.